The United States Food and Drug Administration (FDA) recently announced that it had granted a first-ever approval of a combination treatment for melanoma, the most deadly type of skin cancer. The agency approved the combination of GlaxoSmithKline’s genetically-targeted dabrafenib (Tafinlar™) and trametinib (Mekinist™) for patients with metastatic or unresectable melanoma whose tumors possess either the BRAF V600E or V600K genetic mutations.
New Advances in Treating Hyperpigmentation
This past decade has seen an enormous surge in popularity of skin brightening products formulated specifically to treat hyperpigmentation and…

0 Comments